Standout Papers
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer (2019)
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (2013)
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial (2018)
- Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer (2022)
Immediate Impact
1 by Nobel laureates 6 from Science/Nature 66 standout
Citing Papers
Prostate Cancer
2025 Standout
Renal cell carcinoma
2024 Standout
Works of Brad Rosbrook being referenced
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
2018
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
2013 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Brad Rosbrook | 3087 | 1473 | 1359 | 1723 | 87 | 4.2k | |
| James Stevenson | 2748 | 3464 | 538 | 1183 | 136 | 5.7k | |
| Francesco Perrone | 1769 | 3544 | 852 | 1085 | 187 | 5.7k | |
| Antoine Thiery-Vuillemin | 2249 | 1894 | 942 | 1158 | 154 | 3.5k | |
| Adolfo Favaretto | 2108 | 1670 | 346 | 760 | 135 | 3.6k | |
| Umberto Basso | 1630 | 2043 | 711 | 992 | 232 | 4.5k | |
| Philip J. Stella | 2094 | 3270 | 763 | 992 | 126 | 5.5k | |
| D. Scott Ernst | 2761 | 1709 | 745 | 1189 | 76 | 4.2k | |
| Peter Venner | 4734 | 3210 | 1481 | 1894 | 114 | 8.2k | |
| Randolph S. Marks | 2756 | 2647 | 511 | 1428 | 120 | 5.8k | |
| Nicolas Mottet | 6274 | 1498 | 932 | 946 | 140 | 8.0k |
All Works
Loading papers...